跳至主要内容
临床试验/NCT02486497
NCT02486497已完成不适用

Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining After Curative Surgery of Pancreatic Cancer

Seoul National University Hospital2 个研究点 分布在 2 个国家目标入组 40 人开始时间: 2015年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
40
试验地点
2
主要终点
Recurrence free survival

研究概览

简要总结

Human equilibrative nucleoside transporter 1 (hENT1) is a membrane transporter which is a predicting marker for gemcitabine chemotherapy. However, there is a limited evidence of it as an indicator for adjuvant gemcitabine chemotherapy. In this study, investigators try to investigate the role of hENT1 as a indicator of selection of adjuvant chemotherapy regimen between gemcitabine and 5-fluorouracil (5-FU).

详细描述

After surgical resection of pancreatic cancer, the tissue is immunostained by hENT1 antibody. The grades of immunostaining are categorized as 0 (0%), 1 (<50%), and 2 (>=50%). According to the grade, patients with grade 0 or 1 will be treated with 5-FU and those with grade 2 will be treated with gemcitabine. After the study, investigators will calculate the overall survival and recurrence free survival of the patients and investigate the role of hENT1 as a predictive biomarker for adjuvant gemcitabine chemotherapy.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with curatively resected pancreatic cancer
  • Age between 18 and 75
  • Eastern Cooperative Oncology Group performance score 0 or 1
  • Patients with compliance
  • Patients with informed consent

排除标准

  • Patients refuse to enroll this study
  • Patients with concomitant chemoradiation therapy
  • Previous chemotherapy
  • Pregnant or preparing a pregnancy
  • Uncontrolled infection, diabetes, hypertension, ischemic heart disease, myocardial infarction within 6 months
  • Enrolled another clinical trial within 30 days
  • Patients will be expected to be risk because of enrollment
  • Patients without informed consent

结局指标

主要结局

Recurrence free survival

时间窗: Upto 24 weeks

次要结局

  • Overall survival(Upto 24 weeks)
  • Toxicity(Upto 24 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验